Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Netherlands Cancer Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Collection of follow-up data from the original trial patient cohort.
Collection of follow-up data from the original trial patient cohort by means of structured patient file abstraction, a questionnaire to the general practitioner, and registry consultations.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | Overall survival according to the definition and analysis plan of the original study | 2 years |
| Relapse-free survival | Relapse-free survival according to the definition and analysis plan of the original study | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of cardiovascular events | 2 years | |
| Incidence of malignancies | 2 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with stage II or III breast cancer involving ≥ 4 axillary lymph nodes, who have been treated with adjuvant chemotherapy with or without intensification and hematopoietic stem-cell rescue.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| J A Gietema, MD, PhD | University Medical Center Groningen | Principal Investigator |
| G Sonke, MD, PhD | The Netherlands Cancer Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Academic Medical Center | Amsterdam | Netherlands | ||||
| The Netherlands Cancer Institute |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 12840087 | Background | Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG; Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003 Jul 3;349(1):7-16. doi: 10.1056/NEJMoa022794. | |
| 31999296 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Amsterdam |
| Netherlands |
| VU University Medical Center | Amsterdam | Netherlands |
| Medisch Spectrum Twente | Enschede | Netherlands |
| University Medical Center Groningen | Groningen | Netherlands |
| Leiden University Medical Center | Leiden | Netherlands |
| Maastricht University Medical Center | Maastricht | Netherlands |
| Radboud University Medical Center | Nijmegen | Netherlands |
| Erasmus Medical Center | Rotterdam | Netherlands |
| University Medical Center Utrecht | Utrecht | Netherlands |
| Derived |
| Steenbruggen TG, Steggink LC, Seynaeve CM, van der Hoeven JJM, Hooning MJ, Jager A, Konings IR, Kroep JR, Smit WM, Tjan-Heijnen VCG, van der Wall E, Bins AD, Linn SC, Schaapveld M, Jacobse JN, van Leeuwen FE, Schroder CP, van Tinteren H, de Vries EGE, Sonke GS, Gietema JA. High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Apr 1;6(4):528-534. doi: 10.1001/jamaoncol.2019.6276. |